FR2622798B1 - Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires - Google Patents

Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires

Info

Publication number
FR2622798B1
FR2622798B1 FR8812738A FR8812738A FR2622798B1 FR 2622798 B1 FR2622798 B1 FR 2622798B1 FR 8812738 A FR8812738 A FR 8812738A FR 8812738 A FR8812738 A FR 8812738A FR 2622798 B1 FR2622798 B1 FR 2622798B1
Authority
FR
France
Prior art keywords
treatment
dosage form
delivery device
cardiovascular diseases
osmotic delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR8812738A
Other languages
English (en)
Other versions
FR2622798A1 (fr
Inventor
Davdatt Ayer Atul
R. Swanson David
L. Kuczynski Anthony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of FR2622798A1 publication Critical patent/FR2622798A1/fr
Application granted granted Critical
Publication of FR2622798B1 publication Critical patent/FR2622798B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FR8812738A 1987-10-02 1988-09-29 Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires Expired - Lifetime FR2622798B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/104,006 US4816263A (en) 1987-10-02 1987-10-02 Dosage form for treating cardiovascular diseases comprising isradipine

Publications (2)

Publication Number Publication Date
FR2622798A1 FR2622798A1 (fr) 1989-05-12
FR2622798B1 true FR2622798B1 (fr) 1993-10-15

Family

ID=22298196

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8812738A Expired - Lifetime FR2622798B1 (fr) 1987-10-02 1988-09-29 Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires

Country Status (22)

Country Link
US (1) US4816263A (fr)
JP (1) JP2590235B2 (fr)
KR (1) KR950010151B1 (fr)
AT (1) AT402689B (fr)
AU (1) AU615215B2 (fr)
BE (1) BE1001101A5 (fr)
CA (1) CA1317550C (fr)
CH (1) CH677609A5 (fr)
DE (1) DE3833282C2 (fr)
DK (1) DK175564B1 (fr)
ES (1) ES2011120A6 (fr)
FI (1) FI92554C (fr)
FR (1) FR2622798B1 (fr)
GB (1) GB2210266B (fr)
IE (1) IE61862B1 (fr)
IT (1) IT1234215B (fr)
LU (1) LU87351A1 (fr)
NL (1) NL194748C (fr)
NO (1) NO176466C (fr)
PT (1) PT88618B (fr)
SE (1) SE503471C2 (fr)
ZA (1) ZA887362B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946687A (en) * 1987-10-02 1990-08-07 Alza Corporation Dosage form for treating cardiovascular diseases
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US5208037A (en) * 1991-04-22 1993-05-04 Alza Corporation Dosage forms comprising polymers comprising different molecular weights
US6124355A (en) * 1995-05-22 2000-09-26 Guittard; George V. Oxybutynin therapy
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
US6262115B1 (en) 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US20040062799A1 (en) * 1997-09-29 2004-04-01 Ayer Atul D. Therapeutic composition and delivery system for administering drug
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
AR018321A1 (es) * 1998-03-26 2001-11-14 Alza Corp Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
US20010038855A1 (en) * 1998-06-05 2001-11-08 Desjardin Michael A. Dosage form for administering prescribed dose
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
AU2002345638A1 (en) * 2001-06-11 2002-12-23 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
ES2380287T3 (es) * 2001-06-11 2012-05-10 Xenoport, Inc. Profármacos de análogos de GABA, composiciones y sus usos
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
WO2004053192A1 (fr) * 2002-12-11 2004-06-24 Xenoport, Inc. Formes posologiques administrees oralement de promedicaments analogues de gaba fondu a toxicite reduite
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
WO2005019163A2 (fr) * 2003-08-20 2005-03-03 Xenoport, Inc. Prodrogues a base de carbamate d'alkyle acyle, procede de synthese et utilisation
EP2354120A1 (fr) 2003-08-20 2011-08-10 XenoPort, Inc. Synthèse de promédicaments a base de carbamate d'acyloxyalkyle et leurs intermédiaires
US7700652B2 (en) * 2003-09-11 2010-04-20 Xenoport, Inc. Treating urinary incontinence using prodrugs of GABA analogs
SG146643A1 (en) * 2003-09-17 2008-10-30 Xenoport Inc Treating or preventing restless legs syndrome using prodrugs of gaba analogs
US20060128676A1 (en) * 2004-07-13 2006-06-15 Pharmacofore, Inc. Compositions of nicotinic agonists and therapeutic agents and methods for treating or preventing diseases or pain
US7566738B2 (en) * 2004-11-03 2009-07-28 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of sulfinic acids, methods of synthesis, and use
US7494985B2 (en) * 2004-11-03 2009-02-24 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
MX2007005306A (es) 2004-11-04 2007-06-11 Xenoport Inc Formas de dosis oral de liberacion sostenida de la prodroga gabapentina.
US7351740B2 (en) 2005-06-20 2008-04-01 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US7884136B2 (en) 2005-06-27 2011-02-08 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
WO2007027476A2 (fr) * 2005-08-26 2007-03-08 Xenoport, Inc. Traitement de l'ejaculation prematuree utilisant des prodrogues de gabapentine et de pregabaline
US20070128282A1 (en) * 2005-12-02 2007-06-07 Patel Hasmukh B Oral osmotic drug delivery system
US8217005B2 (en) 2006-05-26 2012-07-10 Signature Therapeutics, Inc. Controlled release of phenolic opioids
WO2008033572A1 (fr) * 2006-09-15 2008-03-20 Xenoport, Inc. Promédicaments à base de carbamate d'acyloxyalkyle, procédés de synthèse et utilisation
JP2010512314A (ja) * 2006-12-08 2010-04-22 ゼノポート，インコーポレーテッド 疾患を治療するためのｇａｂａアナログのプロドラッグの使用
US7419684B2 (en) * 2006-12-22 2008-09-02 Reliant Pharmaceuticals, Inc. System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same
US7714201B2 (en) * 2006-12-22 2010-05-11 Monsanto Technology Llc Cotton variety 781000G
WO2008124121A1 (fr) * 2007-04-06 2008-10-16 Scidose, Llc Polythérapie associant des statines et des 1,4-dihydropyridine-3,5-dicarboxydiesters et combinaisons de ceux-ci
WO2011028234A1 (fr) * 2009-09-04 2011-03-10 Xenoport, Inc. Utilisations de promédicaments acyloxyalkyl carbamates de l'acide tranexamique
WO2012050907A2 (fr) 2010-09-28 2012-04-19 The Regents Of The University Of California Agonistes de gaba dans le traitement de troubles associés au syndrome métabolique et combinaisons de gaba dans le traitement ou la prophylaxie du diabète de type i
CN102349880B (zh) * 2011-10-12 2015-07-22 合肥华方医药科技有限公司 伊拉地平控释片及其制备方法
CN105030726A (zh) * 2015-08-30 2015-11-11 四川百利药业有限责任公司 一种伊拉地平胶囊的制备方法
CA2998708C (fr) 2015-10-01 2019-09-03 Elysium Therapeutics, Inc. Promedicaments d'opioides a poly(sous-unites) resistant au surdosage et a l'abus
US10335406B2 (en) 2015-10-01 2019-07-02 Elysium Therapeutics, Inc. Opioid compositions resistant to overdose and abuse
JP7234130B2 (ja) 2017-03-17 2023-03-07 エリージウム セラピューティクス， インコーポレイテッド 過剰摂取および乱用に対して抵抗性のポリサブユニットオピオイドプロドラッグ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) * 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4063064A (en) * 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
CH639659A5 (de) * 1978-12-18 1983-11-30 Sandoz Ag Neue 1,4-dihydropyridinderivate, deren herstellung und verwendung.
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) * 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
NZ206600A (en) * 1983-05-11 1987-01-23 Alza Corp Osmotic drug delivery device
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
HU198844B (en) * 1984-06-14 1989-12-28 Sandoz Ag Process for producing new galenic pharmaceutical composition ensuring retarded release of active ingredient
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
US4624847A (en) * 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
GB2181053B (en) * 1985-10-01 1990-05-23 Sandoz Ltd Pharmaceutical formulations with controlled release of the active substance
US4723957A (en) * 1986-02-07 1988-02-09 Alza Corp. System for delivering drug with enhanced bioacceptability
US4753802A (en) * 1986-03-19 1988-06-28 Alza Corporation Verapamil dosage form
AU2152888A (en) * 1987-08-25 1989-03-02 Cerra Metal Works Pty. Ltd. Masonry tie
US4816263A (en) * 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine

Also Published As

Publication number Publication date
JP2590235B2 (ja) 1997-03-12
ZA887362B (en) 1989-06-28
AU2293888A (en) 1989-04-06
AT402689B (de) 1997-07-25
NL8802401A (nl) 1989-05-01
US4816263A (en) 1989-03-28
JPH01113316A (ja) 1989-05-02
DK175564B1 (da) 2004-12-06
KR950010151B1 (ko) 1995-09-11
ES2011120A6 (es) 1989-12-16
NO176466B (no) 1995-01-02
SE503471C2 (sv) 1996-06-24
IE882960L (en) 1989-04-02
NO176466C (no) 1995-04-12
NO884259L (no) 1989-04-03
FR2622798A1 (fr) 1989-05-12
DK545088A (da) 1989-04-03
PT88618B (pt) 1993-07-30
IT8867880A0 (it) 1988-09-30
DE3833282A1 (de) 1989-04-20
AU615215B2 (en) 1991-09-26
NL194748B (nl) 2002-10-01
FI92554C (fi) 1994-12-12
FI884526A0 (fi) 1988-09-30
NL194748C (nl) 2003-02-04
DK545088D0 (da) 1988-09-29
ATA242288A (de) 1996-12-15
IT1234215B (it) 1992-05-06
CA1317550C (fr) 1993-05-11
SE8803486L (sv) 1989-04-03
CH677609A5 (fr) 1991-06-14
KR890006218A (ko) 1989-06-12
GB8822852D0 (en) 1988-11-02
SE8803486D0 (sv) 1988-09-30
FI92554B (fi) 1994-08-31
BE1001101A5 (fr) 1989-07-11
IE61862B1 (en) 1994-11-30
DE3833282C2 (de) 1997-02-13
LU87351A1 (fr) 1989-04-06
PT88618A (pt) 1989-07-31
GB2210266B (en) 1991-07-24
NO884259D0 (no) 1988-09-27
GB2210266A (en) 1989-06-07
FI884526A (fi) 1989-04-03

Similar Documents

Publication Publication Date Title
FR2622798B1 (fr) Forme d'apport dose et dispositif osmotique d'administration d'un medicament pour le traitement de maladies cardio-vasculaires
NO306377B1 (no) Doseform for avgivelse av et medikament
HK1003980A1 (en) Dosage form for dispensing drug and human therapy
NO177177C (no) Fremgangsmåte for fremstilling av en flytende doseringsform for oral administrasjon av en farmasöytisk substans
CA2041579A1 (fr) Forme posologique
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
FR2574292B1 (fr) Dispositif osmotique pour l'apport programme de medicaments
PT79319A (en) Intra-pocket drug delivery devices for treatment of periodontal diseases
NZ229518A (en) Pharmaceutical dosage form for the medication of fish: method of administration and (prophylactic) treatment
FR2560044B1 (fr) Dispositif therapeutique osmotique pour l'apport de medicaments
HU883863D0 (en) Process for the preparation of producing and/or portionly form of therapeutical agents
EP0279887A3 (en) Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder
GR1000419B (el) Μορφη δοσολογιας για χορηγηση ανταγωνιστη του ασβεστιου.
FR2510889B1 (fr) Medicament contenant certains phosphates ribofurannosyl-3',5'-cycliques substitues en 6, 8 pour le traitement de maladies proliferatives de la peau
EP0438147A3 (en) Pharmaceutical compositions and dosage forms for the oral administration of calcitonin
MY105798A (en) Treatment of leukocyte dysfunction with gm-csf.
FR2644060B1 (fr) Medicament, notamment pour le traitement de maladies a virus du type herpes cutane, oculaire et genital
KR900009029A (ko) 가축병 치료용 약물을 투여하는 장치
FR2718024B1 (fr) Médicament et composition pharmaceutique pour le traitement de l'inflammation.
FR2600256B1 (fr) Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus
FR2652747B1 (fr) Application d'agents actifs pour la preparation d'un medicament destine au traitement de maladies auto-immunes.
CA2046448A1 (fr) Posologie d'un medicament utilise pour un traitement circadien
FR2622452B1 (fr) Medicament a base de lactobacillus pour la prevention et le traitement des dysbacterioses vaginales
Krasnyuk et al. Treatment of cardiovascular disorders developing in exposure to toxic agents.
FR2648042B1 (fr) Utilisation de phenylethanolaminotetralines pour la preparation de medicaments pour le traitement des affections oculaires